Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia

NEXT STORY
Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe
PREV STORY
A Pharma Marketer’s Guide to Podcast Advertising
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia

NEXT STORY
Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe
PREV STORY
A Pharma Marketer’s Guide to Podcast Advertising
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

VBL Therapeutics to Report Fiscal 2017 Results on March 15

TEL AVIV, Israel, March 09, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage ...

author_avatar
NASDAQ Market News

CDPHP Offers Housing, Hope for Homeless Members

Albany, NY-based health insurer providers affordable housing for at-risk membersAlbany, NY, Dec. 21, 2018 ...

author_avatar
NASDAQ Market News

Wiebe Olijve, wetenschappelijk adviseur van Aduro Biotech en medeoprichter van Aduro Biotech Europe, geëerd met koninklijke onderscheiding

BERKELEY, Californië, Verenigde Staten en OSS, Nederland, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Aduro ...

author_avatar
NASDAQ Market News